Marshall Wace, LLP Oncocyte Corp Transaction History

Marshall Wace, LLP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 14, 2022	SELL	$2.04 - $3.59 $128,960 - $226,945	-63,216 Closed	0 $0
Q3 2021 Nov 15, 2021	SELL	$3.53 - $5.89 $266,557 - $444,765	-75,512 Reduced 54.43%	63,216 $225,000
Q2 2021 Aug 13, 2021	SELL	$3.77 - $6.0 $829,181 - $1.32 Million	-219,942 Reduced 61.32%	138,728 $796,000
Q1 2021 May 17, 2021	BUY	$2.39 - $6.5 $819,430 - $2.23 Million	342,858 Added 2168.34%	358,670 $1.86 Million
Q4 2020 Feb 16, 2021	BUY	$1.38 - $2.63 $21,820 - $41,585	15,812 New	15,812 $38,000
Q2 2019 Aug 14, 2019	SELL	$2.49 - $5.45 $9,847 - $21,554	-3,955 Closed	0 $0
Q1 2019 May 14, 2019	BUY	$1.47 - $5.91 $5,813 - $23,374	3,955 New	3,955 $16,000

411K

Ticker OCX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 118,609,000
Market Cap $278M
Description
OncoCyte Corporation, a molecular diagnostics company, researches, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay....

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

Stay updated on Marshall Wace, LLP with notifications on news.